The pharmaceutical manufacturing sector is undergoing rapid transformation, driven by advances in technology, evolving regulatory frameworks, shifting patient needs, and sustainability imperatives. In this article we summarise the top research- and innovation-driven themes in 2025, and then look ahead to expectations and developments for 2026 and beyond. These trends span digitalisation, manufacturing paradigms, regulation, supply-chain resilience, and green chemistry. The main objective is to create a vivid picture of where the industry lies, where it is headed, and where research opportunities exist. For broader context on digital transformation in healthcare, explore our article on Digital Therapeutics and Remote Health.
1. Digital Manufacturing & AI/ML-Enablement
One of the most compelling research areas in 2025 is the acceleration of digital manufacturing capability within pharma — using artificial intelligence (AI), machine learning (ML), digital twins, Internet of Things (IoT), and automation. This spans from discovery and R&D through to real-time control of manufacturing, predictive maintenance, process optimisation, and quality assurance.
2025 Highlights
Adoption of AI/ML for manufacturing process control: Manufacturers are applying sensor data with ML/AI analytics to forecast downtime, identify anomalies, and tune parameters in near-real time. Digital twin frameworks are emerging: Virtual versions of production lines, equipment, and even whole plants are being used increasingly to model process changes, simulate variability, and aid decision-making. Automation and robotics integration in quality assurance: Automatic inspection, machine vision, robotic performance of repetitive tasks, and data-driven QA are gaining traction.
2026 and Beyond Expectations
Research will expand into agentic AI-driven manufacturing self-optimisation (systems proposing changes autonomously), and more advanced digital twin collaborations that link R&D through manufacturing to clinical outcomes. Further work will be required on human-machine interface: how operators interact with increasingly "smart" manufacturing systems. Studies note that human collaboration in digital twin systems remains under-addressed. Data integrity, cybersecurity, and regulatory acceptance of AI/ML-based decisions will be major research areas — not just the technology itself but governance, validation, and regulatory science. For a deeper understanding of AI's role in healthcare, read The Role of Artificial Intelligence in Medical Research.
2. Continuous Manufacturing & Modular Flexible Production
Conventional pharmaceutical manufacturing (batch-oriented, bulk volumes) is increasingly under pressure from the demand for agility, small lots, rapid time-to-market, and improved cost-performance. Continuous manufacturing and modular/flexible plants are becoming major trends.
2025 Spotlights
Studies demonstrate that continuous bioprocessing (especially for biologics) can significantly lower costs (some claim up to 75%) and enhance titers (e.g., ~4 g/L/day in some systems). Modular "plug-and-produce" facilities, micro-factories, and smaller agile manufacturing units are becoming increasingly popular. These enable high-mix, low-volume production — particularly crucial for personalised and precision medicines. Many reports note the shift from batch to continuous in the small-molecule and solid dosage domain as well.
2026 and Beyond Expectations
In 2026 we expect further expansion of small-lot continuous facilities, especially for advanced therapies and personalised medicines (e.g., cell & gene, modular peptide synthesis). Research will focus on scaling continuous systems (translating from pilot to commercial scale), process control for continuous end-to-end production, real-time release testing (RTRT) in continuous mode, and integration with digital platforms. Modular manufacturing units (prefabricated cleanrooms, mobile/flexible plants) will attract interest in emerging markets for distributed manufacturing closer to patients. These innovations parallel advances in Drug Delivery Systems Innovations where precision and customization are equally critical.
3. Advanced Therapy Modalities, Personalised & Precision Medicine
The pharmaceutical manufacturing landscape is being reshaped by the rise of advanced modalities (cell therapy, gene editing, recombinant proteins, antibody-drug conjugates) and by the growth of personalised and precision medicine approaches.
2025 Highlights
Advanced modalities are growing rapidly; one report cites that between 2019 and 2021 new modalities grew at ~28% CAGR, and by 2024 they accounted for ~55-57% of pipeline value. Personalised medicine accounted for ~38% of approved new molecular entities in 2024 in one source, underscoring the shift toward patient-specific therapies. Research is focusing on novel manufacturing challenges for these modalities: small-batch cell/gene therapy, automation of vector production, closed systems, and demand for high flexibility.
2026 and Beyond Expectations
Manufacturing for advanced modalities will continue to mature in 2026: scalable gene-editing, allogeneic cell therapies, and modular vector manufacturing lines. There will be growing demand for manufacturing platforms able to switch quickly between products (high-mix/low-volume) to enable personalised therapies. The connection between manufacturing processes and clinical/regulatory processes will intensify — for example, manufacturing platforms designed for platform dossiers rather than product by product. Development of manufacturing analytics for cell and gene therapy (e.g., monitoring processes for living cells, non-invasive sensors, closed-loop control) will gain speed. Supply chain and manufacturing location decisions will also adapt: near-patient manufacturing (satellite facilities or modular units) will rise, enabling faster turnaround and personalised release. This will demand new manufacturing research into facility design, biocontainment, and regulatory models for distributed settings. The evolution of advanced therapies is closely linked to Stem Cell Therapy Breakthroughs and their manufacturing requirements.
4. Green Chemistry, Sustainability & Eco-Manufacturing
Manufacturing sustainability is no longer optional. The pharma industry faces increasing focus on green chemistry practices, waste minimisation, energy efficiency, solvent reduction, single-use systems, and low-carbon operations.
2025 Highlights
Reports indicate single-use and continuous manufacturing systems can reduce energy use ~4.5× and reduce waste up to ~19%. Solvents remain a major input (~50% of API inputs in some estimates). There is increasing adoption of biocatalysis, flow-photochemistry, enzyme discovery, and other greener synthetic routes. Packaging and logistics sustainability is emerging under the spotlight (the sustainable pharmaceutical packaging market is set to grow ~15% CAGR for 2025-2034).
2026 and Beyond Expectations
Research will increasingly explore full life-cycle analysis of manufacturing (energy + water + waste + emissions) and develop benchmark metrics for pharma. There will be deeper integration of green chemistry early in process development (APIs, intermediates) as well as adoption of single-use and modular systems that reduce cleaning and downtime. Sustainability will become a differentiator in manufacturing site design and in supplier selection (CDMOs, raw materials). Regulatory and investor pressure for carbon-neutral or low-carbon operations will grow, and research into novel manufacturing routes (flow chemistry, enzyme cascades, solvent-less operations) will expand. These sustainability efforts complement broader initiatives in Pharmaceutical Waste and Environmental Safety.
5. Improved Quality Control, PAT, and Analytics
Quality control is being revolutionised: moving from end-of-line testing to real-time process analytical technology (PAT), predictive quality, digital QA/QC systems, and analytics-driven assurance.
2025 Highlights
The market for analytical testing is set to expand significantly; machine vision, robotic inspection, ML/AI-enabled anomaly detection, eQMS, and LIMS technologies are gaining momentum. Real-time release and online monitoring are increasingly becoming possible, especially in continuous manufacturing environments.
2026 and Beyond Expectations
The shift toward proactive quality management will continue: fewer end-point tests, more built-in quality via data-driven control. Research into PAT for advanced modalities (cell/gene, viral vectors) will grow — for example, in-line viability sensors, metabolic monitoring, and closed-loop process adjustment. There will be stronger integration of quality data with manufacturing operations using dashboards, AI-driven dashboards, and digital twins of quality. Regulators will increasingly accept data-rich submissions, and research will explore how to validate AI/ML systems for quality decision-making. For researchers interested in quality frameworks, our guide on How to Write a Strong Abstract provides useful structure for presenting quality-related research.
6. Supply-Chain Security, Digital Traceability & Anti-Counterfeit
Pharmaceutical manufacturing does not end at the factory gate: supply-chain integrity, traceability, anti-counterfeit measures, digital provenance, and secure logistics are rising in importance.
2025 Highlights
Research is emerging on technologies such as blockchain, protected QR codes, GNSS verification, proof-of-origin, and tamper-resistant traceability systems. Supply-chain cyber-security is becoming a focus (e.g., zero-trust architectures) to protect manufacturing and logistics systems.
2026 and Beyond Expectations
The integration of manufacturing data with supply-chain digital twins will become more common, enabling end-to-end visibility from raw materials to patient. Advanced cryptographic traceability, AI for anomaly detection in logistics, and resilience planning across global manufacturing networks will be researched. With widespread dissemination of personalised therapies and distributed supply chains (modular/flexible manufacturing), traceability across small-batch and distributed environments will become a research issue. Regulatory examination of counterfeit risk, particularly for biologics and advanced therapies, will propel research in this area.
7. Contract Development & Manufacturing Organisations (CDMOs)
As pharma pipelines become more complex, reliance on CDMOs and outsourcing is increasing. This has influenced manufacturing research, technology adoption, and business models.
2025 Highlights
Outsourcing is no longer just standard large-batch chemistry; CDMOs are increasingly expected to support advanced modalities, continuous manufacturing, modular facilities, and personalised production. Business models of CDMOs are transforming to provide flexibility, modular capacity, single-use technologies, and integrated R&D-manufacturing linkages.
Expectations for 2026 and Beyond
Studies will investigate technology transfer issues in CDMO settings: transferring technologies from small-scale or pilot to CDMOs, and facilitating flexible manufacturing platforms. CDMO models for personalised therapies (e.g., small AAV/viral vector runs) will be a research focus: how to scale, ensure quality, manage cost, and maintain agility. Collaborative platforms between pharma firms and CDMOs will generate research in shared digital infrastructure, manufacturing standards, and flexible modular cells.
8. On-Demand, Micro-Factory & Distributed Manufacturing
Supporting many of the trends above is the move toward distributed, flexible, rapid-response manufacturing: micro-factories, plug-and-produce modules, localised production, smaller batch runs, and faster adaptation.
2025 Highlights
Flexible systems are projected to grow, driven by plug-and-produce platforms, micro-factories, and modular facilities. This change is particularly pertinent in personalised medicines (high variety, small lot size) and local manufacturing close to patient markets.
Anticipations for 2026 and Later
Studying facility design for plug-and-produce modules, modularity in cleanrooms, mobile factory units, rapid change-over, and regulatory systems for distributed locations will gain momentum. There will be economic and risk studies of distributed manufacturing compared with centralised large facilities: cost, regulation, supply-chain robustness, and technology reuse. Control systems, digital twins, and remote monitoring will be critical for managing distributed operations and maintaining compliance. These distributed models are reshaping how we think about Telemedicine and Chronic Disease Management through localized production of therapies.
9. Regulatory Evolution, Convergent Regulation & Platform-Based Manufacturing
The regulatory environment is also evolving — with pressure for faster approvals, platform-based dossiers, harmonised global regulation, acceptance of continuous manufacturing and digitalisation, and real-time oversight.
2025 Highlights
Regulatory agencies such as FDA and EMA are increasingly endorsing continuous data-driven approaches, manufacturing digital submissions, and real-time release. There is growing focus on platform technologies (e.g., ADC platforms, viral vector platforms) which have the potential to facilitate regulatory review.
Expectations for 2026 and Beyond
Research in regulatory science will investigate how platforms (manufacturing + regulatory) can minimise time-to-market, how manufacturing data in digital form can enable regulatory submissions, and how real-time data can support post-approval surveillance. We will likely see more regulatory guidance on AI/ML in manufacturing, digital twin validation, and manufacturing flexibility. International harmonisation (e.g., between US, EU, Asia) will become more important in manufacturing research for global supply chains.
10. Workforce, Skills and Organisational Change
While less frequently cited in pure technical research, the human and organisational dimension of pharmaceutical manufacturing transformation is critical. Research is now starting to address the implications of new technologies, workforce training, and organisational readiness for "smart" manufacturing.
2025 Highlights
With increased adoption of automation, AI, continuous manufacturing, and modular facilities, workforce up-skilling is becoming essential (operators who understand data, digital systems, and automation). Research (e.g., in digital twin publications) underlines that operator trust, man-machine interface, and training are critical — technology alone is insufficient.
2026 and Beyond Expectations
Change management, workforce transformation, digital-capable manufacturing culture, and training syllabuses for smart manufacturing will be researched increasingly. The interplay between organisational design (decentralised facilities, flexible manufacturing) and workforce skill-sets (digital natives, data-literate operators) will be a key area. Collaborative research between engineering, manufacturing science, and the social sciences will become more common in pharma manufacturing research.
Looking Ahead: What 2026 Might Bring
As we move into 2026, several of the trends mentioned above will shift to mainstream industrial practice alongside new emerging research frontiers. Key developments include:
Commercial adoption of fully integrated digital manufacturing platforms
By 2026, more pharmaceutical manufacturing plants will deploy connected digital platforms spanning discovery, development, scale-up, manufacturing, and supply chain. These platforms will incorporate digital twins of process, equipment, and facility; AI/ML analytics; predictive maintenance; and closed-loop process control. The number of fully "smart factories" geared for pharmaceutical production will increase. Research opportunities will include how these systems perform under real-world operating conditions, interoperability of data sources, standardisation of digital twin frameworks, and regulatory validation of digital platforms.
Small-batch, personalised medicine production becomes less niche
Manufacturing for personalised and precision medicine will move from experimental to more routine in 2026. Smaller batch sizes, high flexibility, rapid change-over, small-lot production, and near-patient manufacturing will become more common. This shift will require research in toolkits for rapid production fallback, cost models for small-batch manufacturing, change-over strategies, and operational models for near-patient sites (satellite plants). Research will analyse how economies of scale change in this paradigm and how supply chains evolve.
Manufacturing as a differentiator
Beyond cost of goods, manufacturing will become a competitive advantage. Speed to market, manufacturing flexibility, ability to switch between products, resilience, sustainability, and responsiveness to local and regional needs will count. For researchers, this means investigating how manufacturing strategy converges with pipeline strategy, how facility design affects time to market, how manufacturing agility is achieved, and how manufacturing-led innovation can enable therapeutic innovation.
Sustainability and ESG become embedded in manufacturing decision making
By 2026, sustainability will be a core decision parameter: carbon footprint, water use, waste, raw-material sourcing, supplier transparency, and life-cycle metrics. Manufacturing research will increasingly involve modelling and benchmarking sustainable manufacturing operations, evaluating green chemistry routes in pharma process development, designing low-carbon manufacturing sites, and integrating sustainability metrics into regulatory submissions and investor disclosures.
Globalised but agile manufacturing networks
The future will likely see manufacturing networks that are global in reach but agile in deployment: small regional nodes, satellite plants, and mobile/flexible manufacturing units deployed near patient markets or in response to emergent demand. By 2026 this model will gain currency in pharma manufacturing. Research will need to address network design, risk modelling for distributed manufacturing, regulatory oversight of multi-site operations, digital connectivity across nodes, and supply-chain flexibility. These networks parallel innovations in Wearable Health Technology and Remote Patient Monitoring where decentralized data collection supports distributed care models.
Manufacturing research converges across disciplines
As manufacturing becomes more digital, distributed, and agile, research will cross traditional domains. Studies will integrate manufacturing engineering with data analytics, regulatory validation, supply-chain modelling, and workforce transformation. Interdisciplinary research projects will proliferate, exploring topics like digital twins in pharma manufacturing, organisational readiness for continuous manufacturing, regulatory frameworks for modular plants, skills training for smart manufacturing, and supply-chain resilience modelling for distributed production.
Regulatory frameworks become enablers rather than constraints
In 2026 we expect regulatory agencies to issue more guidance and acceptance of new manufacturing paradigms: digital submissions, AI/ML in manufacturing control, continuous manufacturing, platform manufacturing, and modular facilities. Research in regulatory science will explore how to validate AI/ML, how manufacturing data can support submissions, how continuous manufacturing control strategies can satisfy regulators, and how international harmonisation can be achieved.
Workforce transformation and smart manufacturing culture
With new technologies and manufacturing models, by 2026 the workforce will need to evolve — not just new skills but new roles (data-ops, digital manufacturing engineers, process automation specialists, quality analytics officers). Research will investigate how manufacturing organisations transition culture, how training programmes are structured, how digital-native operators integrate with automated systems, and how human-machine collaboration is optimised in pharma manufacturing.
Traceability and supply-chain resilience become must-haves
Manufacturing research will increasingly focus on full life-cycle traceability — from raw material to patient dose — and resilient supply-chain architectures that can respond to disruptions (pandemics, geopolitical events, logistics issues). By 2026 advanced traceability systems (blockchain, encrypted QR codes, digital twins of supply chain) will be more prevalent. Research will examine their implementation in modular/distributed manufacturing, data governance, cybersecurity, and integration with manufacturing operations.
From pilot to scale: bridging the gap between innovation and commercialisation
Many manufacturing technologies (continuous lyophilisation, digital twins, agentic AI, modular plants) are today at pilot or early commercial stage. In 2026 we expect greater work on bridging the "valley of death" from innovation to full commercial scale. Research will delve into how new manufacturing platforms are scaled, industrialised, validated, qualified, and how their economics perform under commercial conditions. Case studies, risk assessments, scale-up methodologies, cost-benefit analyses, and technology transfer research will all feature prominently.
In short, 2026 is likely to mark a transition from "early adopter experiments" to "industrialised deployment" of many manufacturing innovations that have been incubating up to 2025. For researchers and Master's students, this offers fertile ground: the move from bench/pilot to real-world deployment means opportunity for applied research, implementation studies, comparative case studies, and cross-disciplinary collaboration. The manufacturing sciences in pharma are entering a period of significant change — those who align research with these trajectories will be well positioned.
Implications for Researchers & Master's Students
Given this landscape, here are concrete research ideas and directions you may consider:
Process Analytical Technology (PAT) in advanced therapies: Focus on developing sensors, analytics, and control mechanisms for cell/gene therapy manufacturing (e.g., in-line measurement of cell viability or viral vector titres).
Digital twin human-machine collaboration: Investigate how digital twin systems can integrate operator input, and how UI/UX impacts operator trust and decision-making in pharmaceutical manufacturing.
AI/ML validation infrastructures for manufacturing: Create validation methodologies for AI/ML-enabled manufacturing control systems, including risk assessments, regulatory compliance, and data integrity.
Modular manufacturing economics & logistics: Investigate cost-benefit, network design, and supply-chain effects of modular, distributed micro-factory manufacturing of small-batch personalised therapies.
Green chemistry & sustainability metrics: Create life-cycle models comparing traditional vs continuous vs modular manufacturing; evaluate raw-material substitution, enzyme/flow chemistry routes, and waste/energy reduction.
Traceability in distributed manufacturing: Research secure digital traceability systems for distributed manufacturing settings, small-batch sizes, near-patient manufacturing, anti-counterfeit measures, and supply-chain resilience. For researchers studying emerging pharmaceutical topics, our list of Top 10 Pharmaceutical Research Topics for PhD offers additional direction.
Workforce transition and training in pharma manufacturing: Discuss how the pharma manufacturing workforce must change: digital skills, data literacy, operator-automation interaction, and training curriculum design.
Regulatory science for new manufacturing paradigms: Evaluate regulatory pathways, submissions, and platform manufacturing for advanced modalities; utilise digital manufacturing data; model continuous manufacturing acceptance.
For the world of pharma manufacturing, 2025 is a tipping point — an inflection point at which advanced technologies, modalities, and manufacturing models intersect. The research cited above indicates a future where manufacturing will be smarter, more agile, greener, and more embedded in digital and clinical ecosystems.
For researchers and Master's students alike, the prospects are plentiful: the nexus of manufacturing technology, process analytics, advanced therapies, supply-chain resilience, and sustainability delineates many fertile opportunities. As we enter 2026 and beyond, the focus will progressively shift from "what is possible" to "what is scalable, cost-effective, compliant, and resilient in real-world pharma manufacturing." By directing research efforts toward these trends, you not only remain current with industry direction but also position yourself at the leading edge of manufacturing science, regulatory science, and therapeutic innovation. For additional guidance on structuring your research career, see The Reality of a PhD in Pharmaceuticals.
